Literature DB >> 7996469

Stimulatory pathways and sites of action of intrathecally administered nicotinic agents.

I M Khan1, P Taylor, T L Yaksh.   

Abstract

Intrathecal (i.t.) administration of nicotinic agonists to rats elicits a receptor-mediated pressor response, a heart rate increase and irritation-nociceptive behavior. We examined the stimulatory pathways and sites of action of spinally administered nicotinic agonists. The thoracic region appears more sensitive to nicotine-elicited pressor actions than the lumbar or cervical regions of the spinal cord. Nicotinic receptors evoking a nociceptive response appear to be located over an area extending from the lumbar rostrally to the thoracic region. Similar to the pressor response, the thoracic spinal cord is the most sensitive region to nicotine in producing the heart rate increase. The cervical region is the least responsive to nicotine, suggesting sites of actions caudal to the brain stem. Intravenous infusion of trimethaphan inhibited the nicotine-elicited pressor response and tachycardia without affecting the irritation response. This suggests that the cardiovascular responses to spinal nicotinic agonists result from enhanced sympathetic outflow. Intrathecal morphine and MK-801 block spinal nicotine-elicited irritation and tachycardia but not the pressor response, indicating that pressor and irritation responses involve independent receptor-mediated pathways. Tachycardia may be associated with the irritation response. In contrast to nicotine, both pressor and irritation responses to cytisine were blocked by morphine with no effect on heart rate. Spinal transection at the T1-2 level eliminated the nociceptive response to nicotine but not the pressor response. Cytisine responses were similar to nicotine; however, cytisine was significantly less potent as a pressor agent in the transected compared with intact animals.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7996469

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Intrathecal injection of an alpha seven nicotinic acetylcholine receptor agonist attenuates gp120-induced mechanical allodynia and spinal pro-inflammatory cytokine profiles in rats.

Authors:  Lisa C Loram; Jacqueline A Harrison; Lindsey Chao; Frederick R Taylor; Anireddy Reddy; Carissa L Travis; Rona Giffard; Yousef Al-Abed; Kevin Tracey; Steven F Maier; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2010-03-28       Impact factor: 7.217

2.  The Antinociceptive and Antiinflammatory Properties of 3-furan-2-yl-N-p-tolyl-acrylamide, a Positive Allosteric Modulator of α7 Nicotinic Acetylcholine Receptors in Mice.

Authors:  Deniz Bagdas; Katarzyna M Targowska-Duda; Jhon J López; Edwin G Perez; Hugo R Arias; M Imad Damaj
Journal:  Anesth Analg       Date:  2015-11       Impact factor: 5.108

3.  Peripheral nerve injury alters spinal nicotinic acetylcholine receptor pharmacology.

Authors:  Tracey Young; Shannon Wittenauer; Renee Parker; Michelle Vincler
Journal:  Eur J Pharmacol       Date:  2008-06-11       Impact factor: 4.432

4.  Elimination of rat spinal substance P receptor bearing neurons dissociates cardiovascular and nocifensive responses to nicotinic agonists.

Authors:  Imran M Khan; Chris V Wart; Erin A Singletary; Shanaka Stanislaus; Tom Deerinck; Tony L Yaksh; Morton P Printz
Journal:  Neuropharmacology       Date:  2007-10-17       Impact factor: 5.250

5.  Short- and long-term enhancement of excitatory transmission in the spinal cord dorsal horn by nicotinic acetylcholine receptors.

Authors:  Jonathan R Genzen; Daniel S McGehee
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-14       Impact factor: 11.205

6.  The antinociceptive effects of nicotinic receptors α7-positive allosteric modulators in murine acute and tonic pain models.

Authors:  Kelen Freitas; F Ivy Carroll; M Imad Damaj
Journal:  J Pharmacol Exp Ther       Date:  2012-10-31       Impact factor: 4.030

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.